MARSEILLE, France–(BUSINESS WIRE)–Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well … [Read more…]
Cash runway extended through at least February 2023 based upon debt restructuring agreement with IPF Partners (IPF) and equity-linked financing facility with Iris Capital Investment (IRIS) As of June 30, 2022, cash and cash equivalents were EUR 16.1 million (USD 16.8 million) Fast Track and Orphan Drug Designation for PXL065 and PXL770 in adrenoleukodystrophy (ALD) … [Read more…]
Cash runway extended through at least February 2023 based upon debt restructuring agreement with IPF Partners (IPF) and equity-linked financing facility for up to EUR 6 million with Iris Capital Investment (IRIS) Extended cash runway provides added flexibility to capitalize on upcoming Phase 2 DESTINY-1 results for PXL065 in NASH expected this quarter and independently … [Read more…]
SHANGHAI–(BUSINESS WIRE)–#DEL–BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound Library (DEL) technology services in China to help more innovative pharmaceutical companies quickly discover small molecule drugs. X-Chem will leverage its … [Read more…]
Major Defeat for Big Pharma LOS ANGELES–(BUSINESS WIRE)–AIDS Healthcare Foundation welcomes the U.S. Senate’s vote to approve historic legislation empowering Medicare to lower drug prices. “I particularly want to thank President Biden. In his persistent and dogged determination, the president didn’t give up. He prodded, cajoled and pushed his former Senate colleagues to bring home … [Read more…]
SOUTH SAN FRANCISCO, LOS ANGELES, SAN DIEGO & WASHINGTON–(BUSINESS WIRE)–Biocom California, the association representing the life science industry of California, issued the following statement regarding the drug pricing portion in the Inflation Reduction Act. The statement can be attributed to Joe Panetta, Biocom California’s president and CEO: “After a detailed review and consideration of the … [Read more…]
BRANFORD, Conn. & NESS ZIONA, Israel–(BUSINESS WIRE)–BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that the Company will host a conference call and a live audio webcast on Wednesday, August 10, 2022, at 8:00 a.m. EDT, … [Read more…]
In its newest advocacy ad in the Los Angeles Times (Sunday, August 7), AHF sounds an alarm about Los Angeles County’s woefully inadequate response to date to the monkeypox outbreak and urges county officials to designate $10 million—approximately $1 for each LA County resident—to combat monkeypox and STDs AHF also recommends county officials “Put the … [Read more…]
Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the US for the treatment of adult patients with unresectable or … [Read more…]
Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy TOKYO & BASKING RIDGE, N.J.–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) and AstraZeneca’s (LSE/STO/Nasdaq: AZN) ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved in the U.S. for the … [Read more…]
